NUZ
NEURIZON THERAPEUTICS LIMITED
$0.0760
▼ -1.30%
Market cap
$60M
Turnover
$37,415
Last price
$0.0760
Day change
-1.30%
Announcements
14
Range, past year
Open 0.130 · Low 0.053 · Now 0.076 · High 0.185
Open NUZ in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NUZ momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
36/100
Wyckoff phase
Downtrend1d
Trend stage
Breakdown
1 Day
-1.3%
1 Week
-5.0%
1 Month
+35.7%
1 Year
-41.5%
RSI
59
Avg daily range
5.2%
NEURIZON THERAPEUTICS LIMITED scores 36 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 1 trading day. The weekly timeframe reads Accumulation, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- RSI in healthy zone (59)
Points to watch
- 60d drawdown -22.5%
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsNUZ announcements
Recent price-sensitive releases.
- 2026-09-10 Neurizon Announces Partial Redemption of Convertible Notes Issued Capital - Other
- 2026-09-09 NIH funds Expanded Access Program for NUZ-001 in ALS Progress Report
- 2026-09-07 Neurizon Appoints Chief Executive Officer CEO/Managing Director - Appointment Resignation
- 2026-08-25 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-31 Appendix 4C & Quarterly Update Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-31 Neurizon Enters Strategic R&D Financing Facility Debt Facility
- 2026-07-17 HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
More Health Care stocks
Most traded in the same sector.